Modality
ERT
MOA
BCMA ADC
Target
CD38
Pathway
RNA Splicing
BCCMelanomaMDS
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
~Feb 2017
→ ~May 2018
NDA/BLA
Aug 2018
→ Oct 2029
NDA/BLACurrent
NCT07790583
440 pts·BCC
2018-08→2029-10·Terminated
440 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-163.5y awayPh3 Readout· BCC
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-10-16 · 3.5y away
BCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07790583 | NDA/BLA | BCC | Terminated | 440 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A |